## APPENDIX A

Clean PTO-1449 Form

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKETNO.	APPLICATION NO
10177-180-999	10/347,567
APPERCANT	
Tom	
FILING DATE	GROUP
01/17/03	3752

## U.S. PATENT DOCUMENTS

TEXAMINER INITIAL		EXCEMENT NUMBER	DATE	NAME	CLASS	3LECLASS	FILING DATE IF APPROPRIATE
	AA	2XXX/MENT NUMBER 3,773,034	DATE 11/20/73	Burns et al.			
	AB	3,952,742	04/27/76	Taylor		<u> </u>	
	AC	4,296,100	10/20/81	Franco		<u> </u>	
	AD	4,531,936	07/30/85	Gordon		<u>†</u>	<b> </b>
	AE	4,657,536	04/14/87	Dorman		<u> </u>	
	АF	4,770,653	09/13/88	Shiurman		<u>†</u>	<b> </b>
	AG	4,911,148	03/27/90	Sosnowski et al.		<u> </u>	
	AH	4,946,442	08/07/90	Sanagi		<u> </u>	
	ΑI	4,994,033	02/19/91	Shockey et al.			
***************************************	AJ	5,061,273	10/29/91	Yock		<del></del>	<b></b>
	AK.	5,185,004	02/09/93	Lashinski		<u>†</u>	
***************************************	AL	5,203,772	04/20/93	Hammerslag et al.		<del></del>	<b></b>
	AM	5,244,460	09/14/93	Unger et al.		<u>†</u>	
***************************************	AN	5,385,148	01/31/95	Lesh et al.		<del></del>	<b></b>
	AO	5,419,777	05/30/95	Hoffing		<u>†</u>	
	AP	5,489,575	02/06/96	Lee et al.		<u>†</u>	
***************************************	ΛQ	5,499,971	03/19/96	Shapland et al.		<u>†</u>	
	AR	5,507,724	04/16/96	Hofmann et al.			
***************************************	AS	5,569,160	10/29/96	Sauer et al.		<u> </u>	
	AT	5,569,217	10/29/96	l.othet		<u>†</u>	
•••••	AU	5,571,215	11/05/96	Sterman et al.		<u> </u>	
	AV	5,391,195	01/07/97	Taberi et al.			
	AW	5,653,684	08/05/97	Laptewicz et al.		<u> </u>	
	AX	5,661,133 B1	08/26/97	Leiden et al.			
	AY	5,662,124	09/02/97	Wilk		<u> </u>	<del> </del>
***************************************	AZ.	5,693,029	12/02/97	Leonhardt	<del> </del>	<u> </u>	
	BA	5,698,531	12/16/97	Nabel et al.		<u> </u>	<b> </b>
	ВВ	5,733,250	-	Withdrawn		<u> </u>	<b> </b>
	BC	5,733,280	03/31/98	Avitall			
	BD	5,797.870	08/25/98	March et al.		<u> </u>	<b> </b>
	BE	5,797,960	08/25/98	Stevens et al.	<del> </del>	<u> </u>	
	BF	5,820,592	10/13/98	Hammerslag		<u> </u>	
•••••	BG	5,827,216	10/27/98	Igo et al.	<del>-</del>	Ì	
	BH	5,830,993	11/03/98	Blecha et al.	<del></del>	<u> </u>	ļ
	81	5.833,658	11/10/98	Levy et al.	***************************************		

	BJ	5,840,031	11/24/98	Crowley		T		
	BK	5,840,059	11/24/98	March et al.				
	BL.	5,840,062	11/24/98	Gumaste et al.				
	BM	5,843,050	12/01/98	Jones et al.				~~~~~
<b></b>	BN	5,846,221	12/08/98	Snoke et al.				
<b></b>	ВО	5,857,464	01/12/99	Desai				,
	BP	5,860,953	01/19/99	Snoke et al.			•••••	***************************************
	BQ	5,871,495	02/16/99	Mueller				
	BR	5,876,373	03/02/99	Giba et al.				
	BS	5,882,332	03/16/99	Wijay				***************************************
	BT	5,885,272	03/23/99	Aita et al.				
	BU	5,891,133	04/06/99	Murphy-Chutorian				***************************************
	BV	5,931,831	08/03/99	Linder				***************************************
	BW	5,935,063	08/10/99	Nguyen			•••••	***************************************
	BX	5,941,845	08/24/99	Tu et al.				
<u></u>	BY	5,941,868	08/24/99	Kaplan et al.				************
	BZ	5,964,754	10/12/99	Osypka			•••••	***************************************
	CA	5,971,983	10/26/99	Lesh			••••••	
	CB	5,993,443	11/30/99	Murphy-Chutorian et al.			•••••	***************************************
	CC	5,997,525	12/07/99	March et al.			•••••	
	CD	6,004,269	12/21/99	Crowley et al.				
	CE	6,012,457	01/11/00	Lesh			•••••	
	CF	6,624,703	02/15/00	Zanelli et al.				
	CG	6,063,022	05/16/00	Ben-Haim			••••••	
	СН	6,133,233	16/17/06	Ross et al.				
	CI	6,183,444	02/06/01	Olines et al.				
	CI	6,161,543	12/19/00	Cox et al.				
	CK	6,171,303	01/09/01	Ben-Haim et al.				
	CL.	6,179,809	01/30/01	Khairkhahan et al.				
	CM	6,224,584 B1	05/01/01	March et al.				
	CN	6,237,605 B1	05/29/01	Vaska et al.				
	CO	6,309,375	10/30/01	Glines et al.				
	CP	6,314,962 B1	11/13/01	Vaska et al.				
	có	6,314,963 B1	11/13/01	Vaska et al.				
			FOREIG	N PATENT DOCUMENTS				
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBTLASS	TRANSL YES	ATION NO
	CR	WO 96/32129	10/17/96	PCT	·····	Ť		TÖ
	CS	WO 97/25101	07/17/97	PCT	***************************************	<b></b>		
<b></b>	cr	WO 97/47253	12/18/97	PCT	_	<b> </b>	$+\overline{\Box}$	
	CU	WO 99/39624	08/12/99	PCT		<b> </b>		
<b>{</b>		WO 00/57895	1	3	1	1		F

	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)
 CW	Padua et al., "Basic fibroblast growth factor is cardioprotective in ischemia-reperfusion injury" Molecular and Cellular Biochemistry 143: 129-135 (1995)
CX	Shi et al., "PR-39, a proline-rich antibacterial peptide that inhibits phagocyte NADPH oxidase activity by binding to Sre homology 3 domains of p47phox" Proc. Natl. Acad. Sci. 93:6014-6018 (1996)
CY	Uchida et al., "Angiogenic therapy of acute myocardial infarction by intrapericardial injection of basic fibroblast growth factor and heparin sulfate: An experimental study" Am. Heart J., 130:1182-1188 (1995)
CZ	Unger et al. "Basic fibroblast growth factor enhances myocardial collateral flow in a canine model" Am J. Physiol., 266:H1577-H1595 (1994)
DA	Walterberger et al., "Ischemia-Induced Transplant Arterioselerosis in the Rat" Arterioselerosis, Thrombosis and Vascular Biology 16(12):1516-1523 (1996)
DB	Xiaobing, et al. "Ischemia and Reperfusion reduce the Endogenous Basic Fibroblast Growth Factor (bf GF) in Rat Skeletal Muscles" Chinese Medical Journal 108(9): 699-703, (1995)

	EXAMINER	DATE CONSIDERED	
- 1			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609, Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

					ATTY EXCRETE WO		application		•••••
LI	ST O	F REFERENCES CI	TED BY AI	PPLICANT	10177-180-999	<i>)</i>	10/347,56	57	***********
					APPLICANT				
		(Use several sheets	if necessary)		Tom			••••	***********
					FILING DATE		GROUP		
•••••••••••					01/17/03		3752		
			U.S. P.	ATENT DOCUM	IENTS				
*EXAMMER		N	22.100		2.02	-33 1000	ANY 200 2 22	FILING I	DATE
PNITIAL	DC	4,163,204	DATE 07/31/79	Sado et al.	ME	CLASS	SUBCLASS	IF APPROF	WATE:
	DD	4,320,392	03/16/82	Giovinazzo et al					
	DE	4,469,091	09/04/84	Slanetz, Jr					
	DF	4,736,640	04/12/88	Hooks	······				
	DG	4,763,534	08/16/88	Hager					
	DH	4,847,586	07/11/89	Tanaga et al.					
	DI	4,904,184	02/27/90	Murphy et al.			<b> </b>		
	Di	5,339,799	08/23/94	Kami et al.					
•••••	DK	5,341,687	08/30/94	Stan	••••••			•••••	***************************************
	DL	5,396,887	03/14/95	Imran	•••••				***************************************
	DM	5,414,940	05/16/95	Sturdevant					
	DN	5,429,006	07/04/95	Tamori	•••••				*************
	DO	5,520,188	05/28/96	Hennige et al.					
•••••	DP	5,526,703	06/18/96	Aslam et al.				•••••	***************************************
	DQ	5,553,500	09/10/96	Grahn et al.					
	DR	5,578,766	11/26/96	Kondo					
••••	DS	5,583,303	12/10/96	Franz				*****************	***************************************
	Dr	5,604,314	02/18/97	Gralm		<b></b>			
•••••	DU	5,645,531	7/97	Thompson et al.				***************************************	***************************************
	DV	5,725,523	03/10/98	Mueller					•••••
•••••	DW	5,755,714	05/26/98	Murphy-Chutorian				•••••	•••••
•••••	DX.	5,855,577	01/05/99	Murphy-Chutorian	et al.			•••••	***********
	DY	5,886,615	03/23/99	Burgess					•••••
•••••	DΖ	5,891,133	04/06/99	Murphy-Chutorian					************
	EA	5,925,012	07/20/99	Murphy-Chutorian					•••••
•••••	EB	5,989,700	11/23/99	Krivopal					
	EC	6,024,703	02/15/00	Zanelli et al.					•••••
	ED	6,171,276	01/01	Lippe et al.		<u> </u>			
•••••	EE	6,309,370	10/01	Haim et al.					
•••••		s	FOREIG	N PATENT DOC	UMENTS	·····	sl	••••••	•••••
		EXYXMENT NUMBER	DATE	COU	 NIRY	CLASS	SUBCLASS	TRANSL	ATTON
	EF	WO A 9939624	8/12/99	PCT	••••••		}	YES	<del></del>
	E. I	M O W 2A323074	0/12/99	L.C.I					Ш

	*******	EG	EP 0 442 015	2/16/90	EPO			
******					·	 ······································	<b></b>	

	OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

AMINER	DATE CONSIDERED
--------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.